Paul Lizzul compensation by year
ANAPTYSBIO Summary Compensation Table · all 6 fiscal years held| Component | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Salary | $168,205 | $458,000 | $471,740 | $509,479 | $529,859 | $545,754 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $283,440 | $570,993 | $2,128,976 | $505,703 |
| Option awards | $1,238,769 | $1,015,911 | $2,872,730 | $1,131,250 | $1,741,973 | $1,064,476 |
| Non-equity incentive | $67,507 | $216,357 | $174,544 | $203,792 | $158,958 | $221,031 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $104,238 | $8,810 | $10,074 | $25,603 | $23,742 | $28,413 |
| Total | $1,578,719 | $1,699,078 | $3,812,528 | $2,441,117 | $4,583,508 | $2,365,377 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ANAPTYSBIO, INC DEF 14A filed June 29, 2026, accession 0001193125-26-288408, and prior-year filings. Open the filing on EDGAR.
How this page was built: the ANAPTYSBIO, INC filed document, accession 0001193125-26-288408. Every figure is read from that document and cited to the page and table it appears in. Filed June 29, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 50,000 | $2,424,000 | — |
| RSU | 34,100 | $1,653,168 | — |
| RSU | 31,665 | $1,535,119 | — |
| RSU | 12,290 | $595,819 | — |
| Option | 2,917 | — | $30.44 |
| Option | 18,165 | — | $23.23 |
| Option | 60,177 | — | $21.19 |
| Option | 97,200 | — | $14.83 |
Per the Outstanding Equity Awards at Fiscal Year-End table in ANAPTYSBIO, INC's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
1 Form 4 line since the FY2025 proxy (filed June 29, 2026)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-03-12 | Grant or award derivative | — | 16,667 | $0.00 | 16,667 |
The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
ANAPTYSBIO’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Daniel Faga | President and Chief Executive Officer and Director | $6,133,943 |
| Paul Lizzul · this page | Chief Medical Officer | $2,365,377 |
| Dennis Mulroy | Chief Financial Officer | $2,007,927 |
Paul Lizzul's compensation dossier, ANAPTYSBIO
You have read Paul Lizzul's totals and holdings. The dossier adds each equity grant ANAPTYSBIO disclosed for Paul Lizzul and ANAPTYSBIO's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full ANAPTYSBIO compensation record
free company briefThis page is one person within ANAPTYSBIO's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the ANAPTYSBIO proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order ANAPTYSBIO's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ANAPTYSBIO's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order ANAB
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.